Skip to main content
Fig. 4 | BMC Nephrology

Fig. 4

From: Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19

Fig. 4

Forest plot of the incidence of AKI in the remdesivir and no remdesivir subgroups of COVID-19 patients. A total of 972 COVID-19 patients in 5 studies were included in the remdesivir subgroup, and 15,227 patients were included in the no remdesivir subgroup. The pooled estimated incidence of AKI in COVID-19 patients being treated with remdesivir was 7% (95% CI: 3–13%). In the no remdesivir subgroup of COVID-19 patients, the incidence of AKI was 10% (95% CI: 8–13%)

Back to article page